Physician

Amber M Reeves-Daniel, DO

According to 2025 Medicare claims, Amber Reeves-Daniel, DO (NPI: 1184709370) practices nephrology in the Winston-Salem, NC market, with the plurality of this provider's patient population coming from Forsyth, NC. This provider's primary affiliated billing organization is WAKE FOREST UNIVERSITY HEALTH SCIENCES (NPI: 1003803032; TIN: 223849199) and primary practice location at 27157-0001. Reeves-Daniel is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033), participating under the MSSP model.

Reeves-Daniel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 117 traditional Medicare patients, billed 293 HCPCS/CPT codes, and received $23,377 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,425 prescription claims across 180 beneficiaries totaling $106,229 in drug costs, led by Ozempic (Semaglutide). DME data shows 1,677 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $52,376 to $23,377. Similarly, Part D prescription costs have fallen sharply in recent years, from $389,319 to $106,229. For DME billing, reported payments rose steadily, from $355 to $8,341.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	336	719	$52,376
2016	306	812	$56,566
2017	305	821	$53,567
2018	338	670	$42,438
2019	330	826	$47,776
2020	283	796	$41,307
2021	221	472	$40,107
2022	183	390	$33,436
2023	140	272	$23,991
2024	117	293	$23,377

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	247	1,472	$389,319
2016	224	1,461	$587,801
2017	256	2,456	$496,845
2018	331	4,029	$691,247
2019	359	4,045	$493,527
2020	360	4,027	$411,673
2021	297	2,614	$254,213
2022	227	1,709	$207,067
2023	210	1,786	$204,508
2024	180	1,425	$106,229

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	369	1,414	$132,125
2016	374	1,705	$147,604
2017	648	3,152	$254,895
2018	1,121	6,261	$469,648
2019	1,189	6,461	$557,590
2020	1,222	7,331	$764,302
2021	942	4,610	$494,000
2022	581	2,871	$262,273
2023	467	2,480	$152,336
2024	312	1,677	$62,567

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	61	123	$101
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	18	19	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	27	30	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	37	92	$58

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	32	1,066	$30,060
Lokelma	Sodium Zirconium Cyclosilicate	15	516	$14,021
Januvia	Sitagliptin Phosphate	20	600	$10,463
Cinacalcet Hcl	Cinacalcet Hcl	67	3,086	$7,805
Valganciclovir Hcl	Valganciclovir Hcl	38	1,231	$5,253

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	39	$22,313
J7518	Mycophenolic acid, oral, 180 mg	N	48	226	$11,851
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	41	$8,174
J7507	Tacrolimus, immediate release, oral, 1 mg	N	73	344	$7,791
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	91	541	$6,882

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Amber M. Reeves-Daniel, DO?

Tedicare shows public-source Medicare data for Amber M. Reeves-Daniel, DO (NPI 1184709370), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amber M. Reeves-Daniel, DO have ACO affiliation data?

Amber M. Reeves-Daniel, DO is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033).

What billing organization is linked to Amber M. Reeves-Daniel, DO?

Amber M. Reeves-Daniel, DO is linked to WAKE FOREST UNIVERSITY HEALTH SCIENCES (billing NPI 1003803032) in the available physician profile data.

Does Amber M. Reeves-Daniel, DO have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.